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DAS28Introduction: Eosinophilia is reported in several rheumatic diseases including rheumatoid arthritis (RA)
and considered an indicator of high disease activity and a factor of poor prognosis.
Aim of the work: To detect the frequency of eosinophilia in a cohort of RA patients from Kashmir, India
and to study its relation to disease activity.
Patients and methods: This study was conducted on 134 RA patients attending the Rheumatology outpa-
tient clinic, Sher-i-Kashmir Institute of Medical Sciences (SKIMS) Medical Institute. Patients with known
cause associated with eosinophilia such as drug reaction, allergies or helminthic infection were excluded.
The eosinophilic count was recorded and the disease activity score (DAS-28) was calculated.
Results: The patients had a mean age of 36.6 ± 11.5 years and disease duration of 6.8 ± 5.3 years. They
were 103(76.9%) females and 31(23.1%) males (F:M 3.32:1). All the patients were rheumatoid factor pos-
itive. The mean DAS28 was 4.53 ± 0.96 (range: 2.9–7.1). 42(31.3%) had high disease activity. The mean
eosinophilic count was 4.53 ± 3.12% (range 1.1–16.4%) and eosinophilia (>6%) was found in 29(21.6%)
patients with a mean count of 9.4 ± 2.6% (range 6.3–16.4%). The rest of the 105 patients had normal eosi-
nophilic count. The mean eosinophil count was lower in RA patients with high disease activity
(4.14 ± 2.62%). Those RA patients with eosinophilia had a mean DAS28 of 4.4 ± 0.74. A non-significant
negative correlation was present between the eosinophilic count and the DAS28 (r = 0.038, p = 0.66).
None of the eosinophilic patients had any associated pneumonia.
Conclusion: Eosinophilia is quite common in RA patients but does not have any relation with disease
activity.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) is the most common autoimmune
inflammatory arthritis in adults [1]. It has prevalence of slightly
less than 1% in adults [2]. It is a chronic systemic inflammatory dis-
ease of unknown etiology which primarily targets synovial joints
and protean clinical features. RA not only affects health related
quality of life, but also increases mortality [2–4]. Synovial tissues
proliferate in an uncontrolled fashion, resulting in excess fluid pro-
duction, destruction of cartilage, erosion of marginal bone, and
stretching and damage of the tendons and ligaments [2].
It is clear that cytokines play a fundamental role in various
inflammatory processes, articular destruction, and RA-associated
comorbidities [5]. The balance between the activities proinflam-matory and anti-inflammatory cytokines RA patients determines
disease severity [6]. The cytokine imbalance favors the induction
of autoimmunity, chronic inflammation, and thereby joint damage
[7]. Many cytokines were detected as the important biomarkers for
RA patients [8–10].
Traditionally, the monitoring of RA in treat to target strategies
has been based on indices such as the Disease Activity Score with
28-Joint Counts (DAS28) involving formal joint counts performed
by trained professionals [11]. Formal joint counts, though valued
for their information, have been criticized for their use in daily
practice because of their time-consuming nature [12].
Almost all RA patients exhibit some systemic features such as
fatigue, low-grade fevers, anemia and elevations of acute phase
reactants as erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP). This systemic inflammation is believed to be respon-
sible for vascular endothelial damage and a marked increased risk
for coronary artery disease and congestive heart failure in RA
patients [2]. Certain blood picture parameters as mean platelet vol-
ume (MPV) and red blood cell distribution width (RDW) were sig-erience
2 F. Sofi et al. / The Egyptian Rheumatologist xxx (2016) xxx–xxxnificantly higher in RA and similar to ESR and CRP in indicating
inflammatory activity [13].
Eosinophilia, elevated peripheral blood eosinophilic count (>6%
or absolute count >400/mm3) is not uncommon in arthritis
patients especially when they have associated drug reactions,
allergies or helminthic infection [14,15]. Peripheral and tissue eosi-
nophilia can be a prominent feature of several unique rheumato-
logic and vascular diseases [16]. Even though eosinophilia is rare
in recent-onset arthritis suggestive of RA, it is usually directly
related to the rheumatic disease and patients with mild eosinophi-
lia at diagnosis could respond worse to treatment [17]. The risk of
developing eosinophilia appears to be significantly associated with
the presence of rheumatoid factor (RF) auto-antibodies [18]. Eosi-
nophilia in RA has been reported to range from 11% to 63% with an
absolute eosinophilic count of 0.69 to 7.08  109 cells/l and has
been considered as a marker of disease activity [19,20].
The aim of this study was to detect the frequency of eosinophi-
lia in a cohort of RA patients from Kashmir, India and to study its
relation to disease activity.2. Patients and methods
This study was conducted on 134 RA patients attending the
Rheumatology outpatient clinic, Sher-i-Kashmir Institute of Medi-
cal Sciences (SKIMS) Medical Institute, Srinagar, Jammu and Kash-
mir, India. The patients fulfilled the American College of
Rheumatology/European League against Rheumatism (ACR/EULAR)
classification criteria for RA [21]. The disease activity score in 28
joints (DAS-28) was measured for the RA patients [22]. The study
was approved by the local college ethics committee and the study
conforms to the provisions of the Declaration of Helsinki in 1995.
All patients gave their informed consent prior to their inclusion
in the study.
Patients with known cause associated with eosinophilia such as
drug reaction, allergies or helminthic infection were excluded. The
patients were clinical examined and routine laboratory investiga-
tions assessed. The eosinophilic count of the white blood cell
(WBC) differential count was recorded. Eosinophilia was consid-
ered when the absolute count was >400 mm3 or >6% of the differ-
ential WBC count.
2.1. Statistical analysis
The statistics was done using software SPSS 21 describing the
frequency and mean ± SD. Correlation was done using Pearson’s
correlation test. Results were statistically significant at p < 0.05.Figure 1. Correlation between the eosinophilic count and disease activity score
(DAS28) in rheumatoid arthritis patients.3. Results
The study included 134 RA patients with a mean age of
36.6 ± 11.5 years and disease duration of 6.8 ± 5.3 years (range
0.2 and 27 years). They were 103(76.9%) females and 31(23.1%)
males with a female-to-male ratio of 3.32:1. All the patients were
rheumatoid factor (RF) positive. The age of the patients ranged
from 17 to 73 years with only one patient of juvenile onset. The
mean DAS28 was 4.53 ± 0.96 (range: 2.9–7.1). 42 (31.3%) had high
disease activity (DAS28P 5.1) while the rest of the patients
(n = 92; 68.7%) had mild to moderate disease activity
(DAS28 < 5.1).
The mean eosinophilic count was 4.53 ± 3.12% with a range of
1.1% to 16.4% and eosinophilia was found in 29 (21.6%) patients.
The mean eosinophilic count in those 29 patients was 9.4 ± 2.6%
(range 6.3–16.4%). The rest of the 105 patients had normal eosino-
philic count. The mean eosinophil count was lower in RA patients
with high disease activity (4.14 ± 2.62%). Those RA patients withPlease cite this article in press as: Sofi F et al. Eosinophilia in rheumatoid arthr
from Kashmir, India. The Egyptian Rheumatologist (2016), http://dx.doi.org/10eosinophilia had a mean DAS28 of 4.4 ± 0.74. A non-significant
negative correlation was present between the eosinophilic count
and the DAS28 (r = 0.038, p = 0.66) (Fig. 1). None of the eosino-
philic patients had any associated pneumonia.4. Discussion
The role of eosinophilia in connective tissue diseases and the
relationship with symptoms of rheumatic disease have not been
clearly established. Eosinophilia can be seen in various rheumato-
logic conditions but, as corticosteroids are one of the most com-
mon medications used in collagen tissue diseases, the eosinophil
numbers found may be lower than expected and eosinophilia
may be more frequent than reported [23]. Short et al. in 1957
[24] noted a mild eosinophilia in a large number of RA patients.
An increase in the circulating levels of eosinophil cationic protein,
an eosinophil specific granule protein in RA patients has also been
reported [15].
From the Results of the present study it is clear that although
mild eosinophilia is fairly common in RA patients, which was pre-
sent in 29/134 patients (21.6%) there was no correlation between
the eosinophil count and disease activity as assessed by DAS28.
In spite that the presence of eosinophilia in peripheral blood has
been considered as an indicator of bad prognosis in RA patients,
in the study of Chiardola et al. [25] it has been reported that the
frequency of eosinophilia in Argentinean RA patients was 7.33%
and was not an indicator of disease severity of the disease as in
all cases there was evidence for parasitic infection. However our
patients did not have any kind of helminthic infection.
In a retrospective study of 45 RA patients selected for their
severity or elevated RF titers, unexplained eosinophilic counts of
5% or greater were encountered in 40% pointing to a possible rela-
tion to the immune events occurring in the course of RA [26]. Eosi-
nophilia is considered as a poor prognostic factor and associated
with poor response to disease modifying drugs. In a French study,
eosinophilia has been reported to occur in only 3.2% of patients
with new onset arthritis and was associated with poor prognosis
[17] however no such relation was seen in the current study pos-
sibly as a higher level of eosinophilic count, >500/mm3, was con-
sidered as eosinophilia in their study, in addition to the fact that
only new arthritis patient were included and may be also due to
ethnic variation. RA cases with massive eosinophilia have also been
reported [27]. Eosinophilic pneumonia has also been described initis patients and its relation to disease activity: A single center experience
.1016/j.ejr.2016.10.002
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any similar condition. Eosinophilia has also been observed in RA
patients with extra-articular manifestations as subcutaneous nod-
ules, vasculitis, pleural/pericardial involvement or pulmonary
fibrosis [29]. In addition, eosinophilia has been observed as a side
effect of methotrexate in patients with chronic arthritis and may
or may not be accompanied by pancytopenia [26].
Among the limitations of the study is the lack of control sub-
jects and depending on the universal normal value for eosinophilic
count. Involving a larger number of patients in a longitudinal study
and considering the other clinical and laboratory variables as well
as the impact of medications used could add more in-depth to the
reached results. To conclude eosinophilia is quite common in RA
patients but does not have any relation with disease activity.
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